Reaction Details Report a problem with these data
Target
Malignant T-cell-amplified sequence 1
Ligand
BDBM345287
Substrate
n/a
Meas. Tech.
Assay 4: MCT1-Mediated Lactate Transport in BT20 Breast Cancer Cells
IC50
54.5±n/a nM
Citation
 Parnell, KM; McCall, J MCT4 inhibitors for treating disease US Patent  US10202350 Publication Date 2/12/2019 
Target
Name:
Malignant T-cell-amplified sequence 1
Synonyms:
MCT-1 | MCT1 | MCTS1 | MCTS1_HUMAN | Multiple copies T-cell malignancies
Type:
Enzyme Catalytic Domain
Mol. Mass.:
20563.62
Organism:
Homo sapiens (human)
Description:
n/a
Residue:
181
Sequence:
MFKKFDEKENVSNCIQLKTSVIKGIKNQLIEQFPGIEPWLNQIMPKKDPVKIVRCHEHIEILTVNGELLFFRQREGPFYPTLRLLHKYPFILPHQQVDKGAIKFVLSGANIMCPGLTSPGAKLYPAAVDTIVAIMAEGKQHALCVGVMKMSAEDIEKVNKGIGIENIHYLNDGLWHMKTYK
  
Inhibitor
Name:
BDBM345287
Synonyms:
2-[[1-[(2-Chlorophenyl)methyl]-5-[3- (cyclopropylmethoxy)phenyl]pyrazol-3- yl]methoxy]-2-methyl-propanoic acid. 1HNMR (CDCl3): $#948; 0.25-0.29 (m, 2H), 0.58-0.63 (m, 2H), 14.16-1.20 (m, 1H), 1.55 (s, 6H), 5.58 (d, 2H), 4.63 (s, 2H), 5.42 (s, 2H), 6.40 (s, 1H), 6.374-6.78 (m, 2H), 6.84-6.93 (m, 2H), 7.18-7.28 (m, 3H), 7.33-7.35 (m, 1H). | US10202350, Example 33 | US10214492, Example 33 | US11292767, Example 33 | US11724989, Example 33
Type:
Small organic molecule
Emp. Form.:
C25H27ClN2O4
Mol. Mass.:
454.946
SMILES:
CC(C)(OCc1cc(-c2cccc(OCC3CC3)c2)n(Cc2ccccc2Cl)n1)C(O)=O
Structure:
Search PDB for entries with ligand similarity: